article thumbnail

Patient-Centricity: Evolving Digital Communication in Pharma

Pharma Marketing Network

It is a shift from a traditional focus on drug development and marketing to a focus on the patient’s needs. This shift is being driven by advances in digital communication, which are allowing companies to better understand and meet the needs of their patients.

article thumbnail

4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

PharmaVoice

An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA publishes paper on AI/ML in drug development

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has released a discussion paper to complement and inform future guidance on artificial intelligence (AI) and machine learning (ML) in drug development. The post FDA publishes paper on AI/ML in drug development appeared first on European Pharmaceutical Review.

article thumbnail

International regulation: the importance of quality assurance in drug development

European Pharmaceutical Review

As drug development professionals know, global health crises like the COVID-19 pandemic provide the public with valuable insights into how clinical research and regulatory processes work. What are the main challenges quality assurance and compliance professionals face during the drug development and review process?

article thumbnail

Deep Dive: Communications and Commercialisation

pharmaphorum

The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. The pharma company’s senior vice president for major markets talks about the continued evolution of the industry’s approach to communications and commercialisation.

article thumbnail

NEC streamlines AI drug development with subsidiary reshuffle

Pharmafile

Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. All will continue to work with partners in order to move forward with preclinical and clinical development in the infectious diseases and oncology fields. read more

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.